You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorzoxazone
Accession NumberDB00356  (APRD00308)
TypeSmall Molecule
GroupsApproved
DescriptionA centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Structure
Thumb
Synonyms
2-hydroxy-5-chlorobenzoxazole
5-chloro-2-Benzoxazolinone
5-chloro-2-Benzoxazolol
5-chloro-2-Benzoxazolone
5-chloro-2-Hydroxybenzoxazole
5-chloro-2(3H)-benzoxazolone
5-chloro-3H-benzooxazol-2-one
5-Chlorobenzoxazolidone
5-chlorobenzoxazolin-2-one
Chlorzoxane
Chlorzoxazon
Chlorzoxazona
Chlorzoxazone
Chlorzoxazonum
Clorzoxazona
Clorzoxazone
External Identifiers
  • MI 315
  • USAF MA-10
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Parafon Forte Dsctablet500 mg/1oralREMEDYREPACK INC.2012-11-28Not applicableUs
Parafon Forte Dsctablet500 mg/1oralJanssen Pharmaceuticals, Inc.1987-06-15Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorzoxazonetablet500 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-04-12Not applicableUs
Chlorzoxazonetablet500 mg/1oralActavis Pharma, Inc.2011-08-22Not applicableUs
Chlorzoxazonetablet500 mg/1oralProficient Rx LP2011-08-22Not applicableUs
Chlorzoxazonetablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2008-12-23Not applicableUs
Chlorzoxazonetablet500 mg/1oralRebel Distributors Corp2011-08-22Not applicableUs
Chlorzoxazonetablet500 mg/1oralUnit Dose Services2011-08-22Not applicableUs
Chlorzoxazonetablet500 mg/1oralSTAT Rx USA LLC2008-12-23Not applicableUs
Chlorzoxazonetablet500 mg/1oralbryant ranch prepack2008-12-23Not applicableUs
Chlorzoxazonetablet500 mg/1oralClinical Solutions Wholesale2011-08-22Not applicableUs
Chlorzoxazonetablet750 mg/1oralMikart Inc.2010-06-01Not applicableUs
Chlorzoxazonetablet500 mg/1oralPhysicians Total Care, Inc.1995-04-24Not applicableUs
Chlorzoxazonetablet500 mg/1oralRebel Distributors Corp1988-05-04Not applicableUs
Chlorzoxazonetablet500 mg/1occlusive dressing techniqueDispensing Solutions, Inc.2008-12-23Not applicableUs
Chlorzoxazonetablet500 mg/1oralREMEDYREPACK INC.2015-11-17Not applicableUs
Chlorzoxazonetablet375 mg/1oralMikart Inc.2010-06-01Not applicableUs
Chlorzoxazonetablet500 mg/1oralA S Medication Solutions2011-08-22Not applicableUs
Chlorzoxazonetablet500 mg/1oralDispensing Solutions, Inc.2011-01-16Not applicableUs
Chlorzoxazonetablet500 mg/1oralAidarex Pharmaceuticals LLC2011-08-22Not applicableUs
Chlorzoxazonetablet500 mg/1oralDIRECT RX2014-01-01Not applicableUs
Lorzonetablet750 mg/1oralVertical Pharmaceuticals, LLC2011-10-01Not applicableUs
Lorzonetablet375 mg/1oralVertical Pharmaceuticals, LLC2011-10-01Not applicableUs
Parafon Dsctablet500 mg/1oralKeltman Pharmaceuticals Inc.2004-06-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MyoflexinZentiva
ParaflexBioPhausia
RelaxazoneNot Available
RemularNot Available
Remular-SNot Available
SolaxinEisai
Strifon Forte DSCNot Available
Brand mixtures
NameLabellerIngredients
Acetazone ForteTeva Canada Limited
Acetazone Forte C8Teva Canada Limited
Back-aid Forte - TabRougier Pharma Division Of Ratiopharm Inc
Extra Strength Tylenol Aches and StrainsMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Gin Pain Pills - TabStella Pharmaceutical Canada Inc.
Parafon ForteMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.
Parafon Forte C8 W Codeine TabMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.
Parafon Forte TabletsJohnson & Johnson Merck Consumer Pharmaceuticals Of Canada
SaltsNot Available
Categories
UNIIH0DE420U8G
CAS number95-25-0
WeightAverage: 169.565
Monoisotopic: 168.993056084
Chemical FormulaC7H4ClNO2
InChI KeyInChIKey=TZFWDZFKRBELIQ-UHFFFAOYSA-N
InChI
InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
IUPAC Name
5-chloro-2,3-dihydro-1,3-benzoxazol-2-one
SMILES
ClC1=CC2=C(OC(=O)N2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoxazolones. These are organic compounds containing a benzene fused to an oxazole ring (a five-member aliphatic ring with three carbon atoms, one oxygen atom, and one nitrogen atom) bearing a ketone group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxazoles
Sub ClassBenzoxazolones
Direct ParentBenzoxazolones
Alternative Parents
Substituents
  • Benzoxazolone
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Oxazole
  • Azole
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of discomfort associated with acute painful musculoskeletal conditions.
PharmacodynamicsChlorzoxazone, a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Chlorzoxazone is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis. Chlorzoxazone is also a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex a.c. involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles.
Mechanism of actionChlorzoxazone inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Chlorzoxazone also may reduce the release of inflammatory leukotrienes. Chlorzoxazone may act by inhibiting calcium and potassium influx which would lead to neuronal inhibition and muscle relaxation. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding13-18%
Metabolism

Chlorzoxazone is rapidly metabolized in the liver and is excreted in the urine, primarily in a conjugated form as the glucuronide.

SubstrateEnzymesProduct
Chlorzoxazone
6-hydroxychlorzoxazoneDetails
Route of eliminationChlorzoxazone is rapidly metabolized and is excreted in the urine, primarily in a conjugated form as the glucuronide.
Half lifeNot Available
ClearanceNot Available
ToxicityOral, mouse: LD50 = 440 mg/kg; Oral, rat: LD50 = 763 mg/kg; Symptoms of overdose include diarrhea, dizziness, drowsiness, headache, light-headedness, nausea, and vomiting.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.991
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.8733
P-glycoprotein inhibitor INon-inhibitor0.9784
P-glycoprotein inhibitor IINon-inhibitor0.9263
Renal organic cation transporterNon-inhibitor0.9001
CYP450 2C9 substrateNon-substrate0.8243
CYP450 2D6 substrateSubstrate0.6471
CYP450 3A4 substrateNon-substrate0.5372
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9539
CYP450 2D6 inhibitorNon-inhibitor0.9338
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9522
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.7957
CarcinogenicityNon-carcinogens0.9467
BiodegradationNot ready biodegradable0.9655
Rat acute toxicity2.2388 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8675
hERG inhibition (predictor II)Non-inhibitor0.9659
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis totowa llc
  • Barr laboratories inc
  • Mikart inc
  • Mutual pharmaceutical co inc
  • Ohm laboratories inc
  • Par pharmaceutical inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
  • Ortho mcneil pharmaceutical inc
  • Ortho mcneil janssen pharmaceuticals inc
  • Ferndale laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletocclusive dressing technique500 mg/1
Tabletoral375 mg/1
Tabletoral500 mg/1
Tabletoral750 mg/1
Prices
Unit descriptionCostUnit
Parafon forte dsc 500 mg caplet2.65USD caplet
Chlorzoxazone 500 mg tablet0.87USD tablet
Chlorzoxazone 250 mg tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191-191.5Marsh, D.F.; US. Patent 2,895,877; July 21, 1959; assigned to McNeil Laboratories, Inc.
water solubility1000 mg/LNot Available
logP1.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.96 mg/mLALOGPS
logP2.09ALOGPS
logP1.94ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)9.39ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity41.07 m3·mol-1ChemAxon
Polarizability14.94 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Marsh, D.F.; US. Patent 2,895,877; July 21, 1959; assigned to McNeil Laboratories, Inc.

General References
  1. Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF: Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. Epub 2006 Jun 29. [PubMed:16859676 ]
  2. Park JY, Kim KA, Park PW, Ha JM: Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe. J Clin Pharmacol. 2006 Jan;46(1):109-14. [PubMed:16397290 ]
  3. Wan J, Ernstgard L, Song BJ, Shoaf SE: Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats. J Pharm Pharmacol. 2006 Jan;58(1):51-61. [PubMed:16393464 ]
External Links
ATC CodesM03BB73M03BB03M03BB53
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (61.8 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Chlorzoxazone.
AbirateroneThe serum concentration of Chlorzoxazone can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Chlorzoxazone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Chlorzoxazone.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Chlorzoxazone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Chlorzoxazone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Chlorzoxazone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorzoxazone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorzoxazone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorzoxazone.
AmiodaroneThe metabolism of Chlorzoxazone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorzoxazone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorzoxazone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorzoxazone.
AmoxapineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Chlorzoxazone.
AprepitantThe serum concentration of Chlorzoxazone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorzoxazone.
ArtemetherThe metabolism of Chlorzoxazone can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Chlorzoxazone.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlorzoxazone.
AtazanavirThe metabolism of Chlorzoxazone can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Chlorzoxazone can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Chlorzoxazone.
AzelastineChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Chlorzoxazone.
AzithromycinThe metabolism of Chlorzoxazone can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Chlorzoxazone.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Chlorzoxazone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chlorzoxazone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Chlorzoxazone.
BetaxololThe metabolism of Chlorzoxazone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Chlorzoxazone can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Chlorzoxazone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Chlorzoxazone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
BrimonidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorzoxazone.
BrompheniramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Chlorzoxazone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorzoxazone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorzoxazone.
BupropionThe metabolism of Chlorzoxazone can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorzoxazone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorzoxazone.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Chlorzoxazone.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Chlorzoxazone.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Chlorzoxazone.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Chlorzoxazone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorzoxazone.
CaffeineThe metabolism of Chlorzoxazone can be decreased when combined with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chlorzoxazone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorzoxazone.
CarisoprodolThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carisoprodol.
CelecoxibThe metabolism of Chlorzoxazone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Chlorzoxazone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chlorzoxazone.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Chlorzoxazone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorzoxazone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Chlorzoxazone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorzoxazone.
ChloroquineThe metabolism of Chlorzoxazone can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlorphenamine.
ChlorpromazineThe metabolism of Chlorzoxazone can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Chlorzoxazone can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Chlorzoxazone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Chlorzoxazone can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorzoxazone.
CitalopramThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Citalopram.
CitalopramThe metabolism of Chlorzoxazone can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Chlorzoxazone can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Chlorzoxazone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clidinium.
ClobazamThe metabolism of Chlorzoxazone can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Chlorzoxazone.
ClomipramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clomipramine.
ClomipramineThe metabolism of Chlorzoxazone can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorzoxazone.
ClotrimazoleThe metabolism of Chlorzoxazone can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Chlorzoxazone can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clozapine.
CobicistatThe serum concentration of Chlorzoxazone can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Chlorzoxazone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorzoxazone.
ConivaptanThe serum concentration of Chlorzoxazone can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Chlorzoxazone can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorzoxazone.
CyclosporineThe metabolism of Chlorzoxazone can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Chlorzoxazone can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Chlorzoxazone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorzoxazone.
DapoxetineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dapoxetine.
DarifenacinThe metabolism of Chlorzoxazone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Chlorzoxazone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Chlorzoxazone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Chlorzoxazone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Chlorzoxazone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Chlorzoxazone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorzoxazone.
DesipramineThe metabolism of Chlorzoxazone can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Chlorzoxazone.
DexamethasoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorzoxazone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorzoxazone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorzoxazone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorzoxazone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorzoxazone.
DifenoxinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorzoxazone.
DihydroergotamineThe metabolism of Chlorzoxazone can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorzoxazone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorzoxazone.
DiltiazemThe metabolism of Chlorzoxazone can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Chlorzoxazone can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorzoxazone.
DisulfiramThe metabolism of Chlorzoxazone can be decreased when combined with Disulfiram.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Chlorzoxazone.
DoxepinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Doxepin.
DoxycyclineThe metabolism of Chlorzoxazone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
DoxylamineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorzoxazone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
DronedaroneThe metabolism of Chlorzoxazone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlorzoxazone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Chlorzoxazone.
DuloxetineThe metabolism of Chlorzoxazone can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorzoxazone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Chlorzoxazone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Chlorzoxazone.
EfavirenzThe serum concentration of Chlorzoxazone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Efavirenz.
EliglustatThe metabolism of Chlorzoxazone can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chlorzoxazone.
EntacaponeThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Entacapone.
EnzalutamideThe serum concentration of Chlorzoxazone can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Chlorzoxazone can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Chlorzoxazone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorzoxazone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorzoxazone.
EthanolChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Chlorzoxazone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorzoxazone.
EthosuximideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorzoxazone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Chlorzoxazone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorzoxazone.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Chlorzoxazone.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Chlorzoxazone.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Chlorzoxazone.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorzoxazone.
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorzoxazone.
EtravirineThe serum concentration of Chlorzoxazone can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chlorzoxazone.
FenfluramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorzoxazone.
FexofenadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flibanserin.
FluconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Chlorzoxazone.
FlunarizineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Chlorzoxazone.
FluoxetineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluoxetine.
FluoxetineThe metabolism of Chlorzoxazone can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorzoxazone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorzoxazone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorzoxazone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Chlorzoxazone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluvoxamine.
FluvoxamineThe metabolism of Chlorzoxazone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Chlorzoxazone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Chlorzoxazone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Chlorzoxazone.
Fusidic AcidThe serum concentration of Chlorzoxazone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorzoxazone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chlorzoxazone.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Chlorzoxazone.
GuanfacineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Chlorzoxazone.
HaloperidolThe metabolism of Chlorzoxazone can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorzoxazone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorzoxazone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chlorzoxazone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorzoxazone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorzoxazone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
HydroxyzineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Hydroxyzine.
IdelalisibThe serum concentration of Chlorzoxazone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Iloperidone.
ImatinibThe metabolism of Chlorzoxazone can be decreased when combined with Imatinib.
ImipramineThe metabolism of Chlorzoxazone can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Indalpine.
IndinavirThe metabolism of Chlorzoxazone can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Chlorzoxazone can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorzoxazone.
IsoniazidThe metabolism of Chlorzoxazone can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Chlorzoxazone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Chlorzoxazone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorzoxazone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorzoxazone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorzoxazone.
KetoconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chlorzoxazone.
LevocabastineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorzoxazone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorzoxazone.
LidocaineThe metabolism of Chlorzoxazone can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorzoxazone.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorzoxazone.
LopinavirThe metabolism of Chlorzoxazone can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorzoxazone.
LorcaserinThe metabolism of Chlorzoxazone can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Chlorzoxazone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorzoxazone.
Lu AA21004The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Chlorzoxazone can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Chlorzoxazone can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorzoxazone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Chlorzoxazone.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Chlorzoxazone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Chlorzoxazone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorzoxazone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorzoxazone.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorzoxazone.
MetaxaloneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Metaxalone.
MethadoneThe metabolism of Chlorzoxazone can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorzoxazone.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Chlorzoxazone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Chlorzoxazone.
MethocarbamolThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorzoxazone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Chlorzoxazone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorzoxazone.
MethsuximideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorzoxazone.
MetoprololThe metabolism of Chlorzoxazone can be decreased when combined with Metoprolol.
MetyrosineChlorzoxazone may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Chlorzoxazone can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorzoxazone.
MifepristoneThe metabolism of Chlorzoxazone can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
MirabegronThe metabolism of Chlorzoxazone can be decreased when combined with Mirabegron.
MirtazapineChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlorzoxazone.
MitotaneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Chlorzoxazone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Chlorzoxazone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorzoxazone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
NabiloneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Nabilone.
NafcillinThe serum concentration of Chlorzoxazone can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorzoxazone.
NefazodoneThe metabolism of Chlorzoxazone can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Chlorzoxazone can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Chlorzoxazone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Chlorzoxazone can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Chlorzoxazone can be decreased when combined with Nicardipine.
NicotineThe metabolism of Chlorzoxazone can be decreased when combined with Nicotine.
NilotinibThe metabolism of Chlorzoxazone can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chlorzoxazone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorzoxazone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chlorzoxazone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorzoxazone.
NortriptylineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Olanzapine.
OlaparibThe metabolism of Chlorzoxazone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorzoxazone.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorzoxazone.
OrphenadrineChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorzoxazone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Chlorzoxazone.
OsimertinibThe serum concentration of Chlorzoxazone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorzoxazone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorzoxazone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorzoxazone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorzoxazone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorzoxazone.
PalbociclibThe serum concentration of Chlorzoxazone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorzoxazone.
PanobinostatThe metabolism of Chlorzoxazone can be decreased when combined with Panobinostat.
ParaldehydeChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Chlorzoxazone.
ParoxetineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Paroxetine.
ParoxetineThe metabolism of Chlorzoxazone can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Chlorzoxazone can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorzoxazone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorzoxazone.
PerampanelThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Chlorzoxazone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorzoxazone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorzoxazone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlorzoxazone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Chlorzoxazone.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Chlorzoxazone.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorzoxazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorzoxazone.
PipotiazineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pomalidomide.
PosaconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Posaconazole.
PramipexoleChlorzoxazone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Chlorzoxazone.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Chlorzoxazone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorzoxazone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Chlorzoxazone.
PrimidoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chlorzoxazone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorzoxazone.
PromazineThe metabolism of Chlorzoxazone can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorzoxazone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorzoxazone.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Chlorzoxazone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorzoxazone.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Chlorzoxazone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorzoxazone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorzoxazone.
QuinidineThe metabolism of Chlorzoxazone can be decreased when combined with Quinidine.
QuinineThe metabolism of Chlorzoxazone can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ramelteon.
RanolazineThe metabolism of Chlorzoxazone can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorzoxazone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorzoxazone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorzoxazone.
RifabutinThe metabolism of Chlorzoxazone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Chlorzoxazone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Chlorzoxazone can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorzoxazone.
RitonavirThe metabolism of Chlorzoxazone can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Chlorzoxazone can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Chlorzoxazone.
RopiniroleChlorzoxazone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Chlorzoxazone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorzoxazone.
RotigotineChlorzoxazone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorzoxazone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Chlorzoxazone.
SaquinavirThe metabolism of Chlorzoxazone can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorzoxazone.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Chlorzoxazone.
SertralineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Sertraline.
SertralineThe metabolism of Chlorzoxazone can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorzoxazone.
SildenafilThe metabolism of Chlorzoxazone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Chlorzoxazone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Chlorzoxazone can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Chlorzoxazone.
St. John's WortThe serum concentration of Chlorzoxazone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorzoxazone.
SulfisoxazoleThe metabolism of Chlorzoxazone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorzoxazone.
SuvorexantThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tasimelteon.
TelaprevirThe metabolism of Chlorzoxazone can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Chlorzoxazone can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorzoxazone.
TenofovirThe metabolism of Chlorzoxazone can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Chlorzoxazone can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Chlorzoxazone can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Chlorzoxazone.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Chlorzoxazone.
ThalidomideChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorzoxazone.
TheophyllineThe metabolism of Chlorzoxazone can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorzoxazone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorzoxazone.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorzoxazone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorzoxazone.
TiagabineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tiagabine.
TiclopidineThe metabolism of Chlorzoxazone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Chlorzoxazone.
TipranavirThe metabolism of Chlorzoxazone can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tizanidine.
TocilizumabThe serum concentration of Chlorzoxazone can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorzoxazone.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorzoxazone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorzoxazone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Chlorzoxazone.
TranylcypromineThe metabolism of Chlorzoxazone can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorzoxazone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorzoxazone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorzoxazone.
TrimipramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chlorzoxazone.
VemurafenibThe serum concentration of Chlorzoxazone can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Chlorzoxazone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Chlorzoxazone can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Vilazodone.
VoriconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Chlorzoxazone.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorzoxazone.
ZiconotideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zimelidine.
ZiprasidoneThe metabolism of Chlorzoxazone can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Chlorzoxazone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlorzoxazone.
ZonisamideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorzoxazone.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Chlorzoxazone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorzoxazone.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Voltage-gated potassium channel activity
Specific Function:
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key ...
Gene Name:
KCNMA1
Uniprot ID:
Q12791
Molecular Weight:
137558.115 Da
References
  1. Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF: Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. Epub 2006 Jun 29. [PubMed:16859676 ]
  2. Alvina K, Khodakhah K: KCa channels as therapeutic targets in episodic ataxia type-2. J Neurosci. 2010 May 26;30(21):7249-57. doi: 10.1523/JNEUROSCI.6341-09.2010. [PubMed:20505091 ]
  3. Syme CA, Gerlach AC, Singh AK, Devor DC: Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels. Am J Physiol Cell Physiol. 2000 Mar;278(3):C570-81. [PubMed:10712246 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  2. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636 ]
  3. Ernstgard L, Warholm M, Johanson G: Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br J Clin Pharmacol. 2004 Aug;58(2):190-200. [PubMed:15255802 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Wiercinska P, Squires EJ: Chlorzoxazone metabolism by porcine cytochrome P450 enzymes and the effect of cytochrome b5. Drug Metab Dispos. 2010 May;38(5):857-62. doi: 10.1124/dmd.109.030528. Epub 2010 Feb 17. [PubMed:20164110 ]
  2. Warrington JS, Court MH, Greenblatt DJ, von Moltke LL: Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats. J Pharm Pharmacol. 2004 Jun;56(6):819-25. [PubMed:15231049 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Yang TJ, Sai Y, Krausz KW, Gonzalez FJ, Gelboin HV: Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 Oct;8(5):375-82. [PubMed:9825829 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Shimada T, Tsumura F, Yamazaki H: Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80. [PubMed:10534312 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Gorski JC, Jones DR, Wrighton SA, Hall SD: Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica. 1997 Mar;27(3):243-56. [PubMed:9141232 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Shimada T, Tsumura F, Yamazaki H: Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80. [PubMed:10534312 ]
  3. Gorski JC, Jones DR, Wrighton SA, Hall SD: Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica. 1997 Mar;27(3):243-56. [PubMed:9141232 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23